Herskovits Adrianna Zara, Johnson William T, Oved Joseph H, Irwin Spencer, Doddi Sital, John Deronna, Ocasio Angelica, Ramanathan Lakshmi V
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US.
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US.
Am J Clin Pathol. 2025 Jan 28;163(1):80-86. doi: 10.1093/ajcp/aqae097.
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening condition characterized by a massive overactivation of the immune system. Because the clinical findings are nonspecific, the development of assays to facilitate rapid diagnosis is critical for patient care. The objectives of this study were to evaluate the performance of a microfluidic enzyme-linked immunosorbent assay (ELISA) for HLH biomarkers and investigate the impact of insourcing this testing on workflow, cost, and turnaround time in a tertiary-care cancer hospital.
Trends in order volume were evaluated for C-X-C motif chemokine ligand 9 (CXCL9) and soluble interleukin 2 receptor ɑ (sIL2R), and a microfluidic ELISA was used to measure these analytes in serum samples. Analyte values, turnaround time, and costs were compared for this assay relative to reference laboratory testing.
Test ordering has increased from 187 to 1030 requests annually over the past 5 years. Insourcing these analytes on a semiautomated ELISA can decrease time to result by approximately 2 days and generate a cost savings of roughly $140,000 annually within our laboratory.
Using a semiautomated ELISA for sIL2R and CXCL9 may help physicians arrive at a diagnosis and monitor therapy for patients with HLH while decreasing turnaround time and costs within the clinical laboratory.
噬血细胞性淋巴组织细胞增生症（HLH）是一种罕见的、危及生命的疾病，其特征是免疫系统大量过度激活。由于临床表现不具有特异性，因此开发有助于快速诊断的检测方法对于患者护理至关重要。本研究的目的是评估用于HLH生物标志物的微流控酶联免疫吸附测定（ELISA）的性能，并调查在一家三级癌症医院开展此项检测对工作流程、成本和周转时间的影响。
评估了C-X-C基序趋化因子配体9（CXCL9）和可溶性白细胞介素2受体α（sIL2R）的订单量趋势，并使用微流控ELISA检测血清样本中的这些分析物。将该检测方法的分析物值、周转时间和成本与参考实验室检测进行比较。
在过去5年中，检测订单从每年187份增加到1030份。在半自动ELISA上开展这些分析物的检测，可使出结果时间缩短约2天，并且每年可为我们实验室节省约14万美元的成本。
使用半自动ELISA检测sIL2R和CXCL9，可能有助于医生对HLH患者进行诊断和监测治疗，同时缩短临床实验室的周转时间并降低成本。
